Balyasny Asset Management
TGTX icon

Balyasny Asset Management’s TG Therapeutics TGTX Stock Holding History

Balyasny Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-183,823
Closed -$6M – 3554
2025
Q3 		$6.64M Sell
183,823
-512,302
-74% -$16.9M 0.01% 1245
2025
Q2 		$25.1M Buy
+696,125
New +$25.9M 0.04% 577
2025
Q1 		– Sell
-9,100
Closed -$306K – 3278
2024
Q4 		$274K Buy
+9,100
New +$261K ﹤0.01% 2430
2024
Q3 		– Sell
-802,003
Closed -$14.3M – 3162
2024
Q2 		$14.3M Buy
+802,003
New +$12.8M 0.03% 739
2024
Q1 		– Sell
-425,099
Closed -$7.26M – 3114
2023
Q4 		$7.26M Buy
425,099
+278,756
+190% +$3.24M 0.01% 983
2023
Q3 		$1.22M Sell
146,343
-570,621
-80% -$7.96M ﹤0.01% 1514
2023
Q2 		$17.8M Buy
716,964
+361,716
+102% +$9.34M 0.04% 570
2023
Q1 		$5.34M Buy
+355,248
New +$5.4M 0.01% 1046
2022
Q4 		– Sell
-10,499
Closed -$62K – 3234
2022
Q3 		$62K Buy
+10,499
New +$68.9K ﹤0.01% 2454
2022
Q2 		– Sell
-581,587
Closed -$5.53M – 3174
2022
Q1 		$5.53M Buy
581,587
+315,411
+118% +$3.65M 0.02% 912
2021
Q4 		$5.06M Buy
+266,176
New +$6.91M 0.02% 843
2020
Q2 		– Sell
-25,707
Closed -$253K – 1479
2020
Q1 		$253K Buy
+25,707
New +$325K ﹤0.01% 1015
2018
Q4 		– Sell
-102,571
Closed -$574K – 1754
2018
Q3 		$574K Buy
102,571
+50,511
+97% +$577K ﹤0.01% 1338
2018
Q2 		$685K Buy
+52,060
New +$716K ﹤0.01% 1240

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Balyasny Asset Management's TGTX Position: Q4 2025 in Review

Balyasny Asset Management sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 183,823 shares — an estimated $6M sold.

Balyasny Asset Management first reported a position in TGTX in Q2 2018 and held it in 14 quarters. The position peaked at $25.1M in Q2 2025. 351 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • Balyasny Asset Management reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 183,823 TG Therapeutics shares in Q4 2025, an estimated $6M.
  • Balyasny Asset Management first reported a position in TG Therapeutics in Q2 2018 and held it in 14 quarters.
  • Balyasny Asset Management's TG Therapeutics position peaked at $25.1M in Q2 2025.
  • 351 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.